Efficient Production of 2'-fucosyllactose from Fructose Through Metabolically Engineered Recombinant Escherichia Coli

Overview

Journal Microb Cell Fact

Publisher Biomed Central

Specialties Biotechnology
Microbiology

Date 2024 Feb 2

PMID 38303005

Authors

Ran You

Lei Wang

Meirong Hu

Yong Tao

Affiliations

Soon will be listed here.

Abstract

Background: The biosynthesis of human milk oligosaccharides (HMOs) using several microbial systems has garnered considerable interest for their value in pharmaceutics and food industries. 2'-Fucosyllactose (2'-FL), the most abundant oligosaccharide in HMOs, is usually produced using chemical synthesis with a complex and toxic process. Recombinant E. coli strains have been constructed by metabolic engineering strategies to produce 2'-FL, but the low stoichiometric yields (2'-FL/glucose or glycerol) are still far from meeting the requirements of industrial production. The sufficient carbon flux for 2'-FL biosynthesis is a major challenge. As such, it is of great significance for the construction of recombinant strains with a high stoichiometric yield.

Results: In the present study, we designed a 2'-FL biosynthesis pathway from fructose with a theoretical stoichiometric yield of 0.5 mol 2'-FL/mol fructose. The biosynthesis of 2'-FL involves five key enzymes: phosphomannomutase (ManB), mannose-1-phosphate guanylytransferase (ManC), GDP-D-mannose 4,6-dehydratase (Gmd), and GDP-L-fucose synthase (WcaG), and α-1,2-fucosyltransferase (FucT). Based on starting strain SG104, we constructed a series of metabolically engineered E. coli strains by deleting the key genes pfkA, pfkB and pgi, and replacing the original promoter of lacY. The co-expression systems for ManB, ManC, Gmd, WcaG, and FucT were optimized, and nine FucT enzymes were screened to improve the stoichiometric yields of 2'-FL. Furthermore, the gene gapA was regulated to further enhance 2'-FL production, and the highest stoichiometric yield (0.498 mol 2'-FL/mol fructose) was achieved by using recombinant strain RFL38 (SG104ΔpfkAΔpfkBΔpgi119-lacYΔwcaF::119-gmd-wcaG-manC-manB, 119-AGGAGGAGG-gapA, harboring plasmid P30). In the scaled-up reaction, 41.6 g/L (85.2 mM) 2'-FL was produced by a fed-batch bioconversion, corresponding to a stoichiometric yield of 0.482 mol 2'-FL/mol fructose and 0.986 mol 2'-FL/mol lactose.

Conclusions: The biosynthesis of 2'-FL using recombinant E. coli from fructose was optimized by metabolic engineering strategies. This is the first time to realize the biological production of 2'-FL production from fructose with high stoichiometric yields. This study also provides an important reference to obtain a suitable distribution of carbon flux between 2'-FL synthesis and glycolysis.

Citing Articles

High-throughput optimization of organic carbon provision strategies enables enhanced arachidonic acid production in novel microalgae.

Sim E, Lee Y, Park S, Kim G, Shin B, Yun J Microb Cell Fact. 2024; 23(1):290.

PMID: 39443949 PMC: 11515633. DOI: 10.1186/s12934-024-02560-5.

References

Wu K, Chen Y, Bae E, Song Y, Min W, Yu S . Human Milk Oligosaccharide 2'-Fucosyllactose Reduces Neurodegeneration in Stroke Brain. Transl Stroke Res. 2020; 11(5):1001-1011. DOI: 10.1007/s12975-019-00774-z. View

Brockman I, Prather K . Dynamic knockdown of E. coli central metabolism for redirecting fluxes of primary metabolites. Metab Eng. 2014; 28:104-113. PMC: 4355230. DOI: 10.1016/j.ymben.2014.12.005. View

Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M . Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol. 2006; 2:2006.0008. PMC: 1681482. DOI: 10.1038/msb4100050. View

Tang E, Shen X, Wang J, Sun X, Yuan Q . Synergetic utilization of glucose and glycerol for efficient myo-inositol biosynthesis. Biotechnol Bioeng. 2020; 117(4):1247-1252. DOI: 10.1002/bit.27263. View

Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst K, Maciuk A . Safety of 2'-fucosyllactose (2'-FL) produced by a derivative strain (APC199) of ATCC 13032 as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J. 2022; 20(12):e07647. PMC: 9749449. DOI: 10.2903/j.efsa.2022.7647. View

Zhu Y, Wan L, Li W, Ni D, Zhang W, Yan X . Recent advances on 2'-fucosyllactose: physiological properties, applications, and production approaches. Crit Rev Food Sci Nutr. 2021; 62(8):2083-2092. DOI: 10.1080/10408398.2020.1850413. View

Wan L, Zhu Y, Chen G, Luo G, Zhang W, Mu W . Efficient Production of 2'-Fucosyllactose from l-Fucose Self-Assembling Multienzyme Complexes in Engineered . ACS Synth Biol. 2021; 10(10):2488-2498. DOI: 10.1021/acssynbio.1c00102. View

Zhang Q, Liu Z, Xia H, Huang Z, Zhu Y, Xu L . Engineered Bacillus subtilis for the de novo production of 2'-fucosyllactose. Microb Cell Fact. 2022; 21(1):110. PMC: 9164505. DOI: 10.1186/s12934-022-01838-w. View

Vandenplas Y, Berger B, Carnielli V, Ksiazyk J, Lagstrom H, Sanchez Luna M . Human Milk Oligosaccharides: 2'-Fucosyllactose (2'-FL) and Lacto-N-Neotetraose (LNnT) in Infant Formula. Nutrients. 2018; 10(9). PMC: 6164445. DOI: 10.3390/nu10091161. View

10.

Thomason L, Costantino N, Court D . E. coli genome manipulation by P1 transduction. Curr Protoc Mol Biol. 2008; Chapter 1:1.17.1-1.17.8. DOI: 10.1002/0471142727.mb0117s79. View

11.

Li M, Luo Y, Hu M, Li C, Liu Z, Zhang T . Module-Guided Metabolic Rewiring for Fucosyllactose Biosynthesis in Engineered with Lactose Pathway. J Agric Food Chem. 2022; 70(46):14761-14770. DOI: 10.1021/acs.jafc.2c05909. View

12.

Parschat K, Schreiber S, Wartenberg D, Engels B, Jennewein S . High-Titer Biosynthesis of the Predominant Human Milk Oligosaccharide 2'-Fucosyllactose from Sucrose in . ACS Synth Biol. 2020; 9(10):2784-2796. DOI: 10.1021/acssynbio.0c00304. View

13.

Chen Y, Zhu Y, Wang H, Chen R, Liu Y, Zhang W . De novo biosynthesis of 2'-fucosyllactose in a metabolically engineered Escherichia coli using a novel ɑ1,2-fucosyltransferase from Azospirillum lipoferum. Bioresour Technol. 2023; 374:128818. DOI: 10.1016/j.biortech.2023.128818. View

14.

Kornberg H . Routes for fructose utilization by Escherichia coli. J Mol Microbiol Biotechnol. 2001; 3(3):355-9. View

15.

Li C, Li M, Hu M, Zhang T . Metabolic Engineering of De Novo Pathway for the Production of 2'-Fucosyllactose in Escherichia coli. Mol Biotechnol. 2023; 65(9):1485-1497. DOI: 10.1007/s12033-023-00657-7. View

16.

Wallingford J, Myers P, Barber C . Effects of addition of 2-fucosyllactose to infant formula on growth and specific pathways of utilization by in healthy term infants. Front Nutr. 2022; 9:961526. PMC: 9539000. DOI: 10.3389/fnut.2022.961526. View

17.

Yamamoto N, Nakahigashi K, Nakamichi T, Yoshino M, Takai Y, Touda Y . Update on the Keio collection of Escherichia coli single-gene deletion mutants. Mol Syst Biol. 2009; 5:335. PMC: 2824493. DOI: 10.1038/msb.2009.92. View

18.

Lin L, Gong M, Liu Y, Li J, Lv X, Du G . Combinatorial metabolic engineering of Escherichia coli for de novo production of 2'-fucosyllactose. Bioresour Technol. 2022; 351:126949. DOI: 10.1016/j.biortech.2022.126949. View

19.

Baumgartner F, Seitz L, Sprenger G, Albermann C . Construction of Escherichia coli strains with chromosomally integrated expression cassettes for the synthesis of 2'-fucosyllactose. Microb Cell Fact. 2013; 12:40. PMC: 3655002. DOI: 10.1186/1475-2859-12-40. View

20.

Alliet P, Vandenplas Y, Roggero P, Jespers S, Peeters S, Stalens J . Safety and efficacy of a probiotic-containing infant formula supplemented with 2'-fucosyllactose: a double-blind randomized controlled trial. Nutr J. 2022; 21(1):11. PMC: 8862345. DOI: 10.1186/s12937-022-00764-2. View